Transfer factor in prevention of Burkitt's lymphoma relapses.
Twenty-two African children with endemic Burkitt's lymphoma entered a study to evaluate the possible efficacy of a transfer factor (TF) with specific activity against Eptein-Barr virus in preventing disease relapses. Five of eleven patients have so far relapsed in the non TF-treated group as against two of eleven in the TF-treated group. The patterns of relapse and observable increased disease free remission duration in the TF-treated group strongly suggest a beneficial effect particularly in the prevention of late relapses. A larger series of patients treated with this specific TF are needed to confirm these observations in endemic Burkitt's lymphoma.
Nkrumah
F K
FK
Burkitt Tumour Project, Univ. of Ghana Medical Sch. Accra.
Pizza
G
G
Neequaye
J
J
Viza
D
D
De Vinci
C
C
Levine
P H
PH
D000293:Adolescent; D002051:Burkitt Lymphoma / Q000517:prevention & control* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D012008:Recurrence; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor